UTHR - Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity | Benzinga
On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported first-quarter sales of $677.7 million, up 34% year over year, beating the consensus of $623.9 million.
The company reported EPS of $6.17, up from $4.86 a year ago, surpassing the consensus of $5.56.
“The first quarter of 2024 represents another quarter of record revenue and double-digit year-over-year revenue growth,” jointly said Martine Rothblatt, Chairperson and Chief Executive Officer and Michael Benkowitz, President and Chief Operating Officer.
“That growth, coupled with our upcoming clinical reads, puts us ...